Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Clinical Trial to evaluate the Efficacy and Safety of a combination regimen of MK 5172 with/without MK 8742 and/or Ribavirin (RBV) in Subjects with Chronic Hepatitis C Genotypes 2, 4, 5 and 6 Infection

Trial Profile

Phase II Clinical Trial to evaluate the Efficacy and Safety of a combination regimen of MK 5172 with/without MK 8742 and/or Ribavirin (RBV) in Subjects with Chronic Hepatitis C Genotypes 2, 4, 5 and 6 Infection

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Feb 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elbasvir (Primary) ; Grazoprevir (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms C-SCAPE
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 19 Feb 2019 Results of integrated analysis of data from 12 international phase 2/3 clinical trials(NCT01717326,NCT01932762,NCT02092350,NCT02105467,NCT02105662,NCT02105688,NCT02105701,NCT02115321,NCT02203149,NCT02251990,NCT02252016 and NCT02358044) assessing safety and efficacy of Elbasvir/Grazoprevir in Asian Participants with Hepatitis C Virus Genotypes 1 and 4 Infection published in the Journal of Gastroenterology and Hepatology
    • 31 Aug 2018 Biomarkers information updated
    • 26 Apr 2018 Results of retrospective analysis of black participants receiving elbasvir/grazoprevir (EBR/GZR) in nine phase 2/3 clinical trials (C-SURFER (NCT02092350); C-EDGE COINFECTION (NCT02105662) ; C-EDGE TREATMENT-NAIVE (NCT02105467/protocol PN060) ; C-EDGE TREATMENT-EXPERIENCED (NCT02105701/protocol PN068) ; C-WORTHY (NCT01717326/protocol PN035); C-EDGE IBLD (NCT02252016/protocol PN065), and C-EDGE COSTAR (NCT02105688/protocol PN062)) published in the American Journal of Gastroenterology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top